Autolus Therapeutics

2.23
0.01 (0.45%)
At close: Jan 17, 2025, 3:59 PM
2.33
4.71%
After-hours Jan 17, 2025, 04:50 PM EST

Autolus Therapeutics Statistics

Share Statistics

Autolus Therapeutics has 266.12M shares outstanding. The number of shares has increased by 0.07% in one year.

Shares Outstanding 266.12M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.03%
Owned by Institutions (%) n/a
Shares Floating 236.67M
Failed to Deliver (FTD) Shares 1.92K
FTD / Avg. Volume 0.1%

Short Selling Information

The latest short interest is 7.68M, so 2.89% of the outstanding shares have been sold short.

Short Interest 7.68M
Short % of Shares Out 2.89%
Short % of Float 3.25%
Short Ratio (days to cover) 3.88

Valuation Ratios

The PE ratio is -5.38 and the forward PE ratio is -4.56.

PE Ratio -5.38
Forward PE -4.56
PS Ratio 659.71
Forward PS 3.8
PB Ratio 10.05
P/FCF Ratio -7.15
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Autolus Therapeutics has an Enterprise Value (EV) of 933.59M.

EV / Earnings -4.48
EV / Sales 549.82
EV / EBITDA -5.96
EV / EBIT -4.79
EV / FCF -5.96

Financial Position

The company has a current ratio of 6.15, with a Debt / Equity ratio of 0.48.

Current Ratio 6.15
Quick Ratio 6.15
Debt / Equity 0.48
Total Debt / Capitalization 32.21
Cash Flow / Debt -2.75
Interest Coverage -4.33

Financial Efficiency

Return on equity (ROE) is -1.87% and return on capital (ROIC) is -118.59%.

Return on Equity (ROE) -1.87%
Return on Assets (ROA) -0.56%
Return on Capital (ROIC) -118.59%
Revenue Per Employee 3.67K
Profits Per Employee -450.07K
Employee Count 463
Asset Turnover 0
Inventory Turnover 0

Taxes

Income Tax -19.00K
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by -63.5% in the last 52 weeks. The beta is 2.04, so Autolus Therapeutics's price volatility has been higher than the market average.

Beta 2.04
52-Week Price Change -63.5%
50-Day Moving Average 2.79
200-Day Moving Average 3.79
Relative Strength Index (RSI) 38.18
Average Volume (20 Days) 1.90M

Income Statement

In the last 12 months, Autolus Therapeutics had revenue of 1.70M and earned -208.38M in profits. Earnings per share was -1.2.

Revenue 1.70M
Gross Profit -4.87M
Operating Income -195.03M
Net Income -208.38M
EBITDA -156.77M
EBIT -195.03M
Earnings Per Share (EPS) -1.2
Full Income Statement

Balance Sheet

The company has 239.57M in cash and 52.97M in debt, giving a net cash position of 186.60M.

Cash & Cash Equivalents 239.57M
Total Debt 52.97M
Net Cash 186.60M
Retained Earnings -878.56M
Total Assets 827.49M
Working Capital 665.64M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -145.59M and capital expenditures -10.99M, giving a free cash flow of -156.57M.

Operating Cash Flow -145.59M
Capital Expenditures -10.99M
Free Cash Flow -156.57M
FCF Per Share -0.9
Full Cash Flow Statement

Margins

Gross margin is -286.63%, with operating and profit margins of -11.49K% and -12.27K%.

Gross Margin -286.63%
Operating Margin -11.49K%
Pretax Margin -12.27K%
Profit Margin -12.27K%
EBITDA Margin -9.23K%
EBIT Margin -11.49K%
FCF Margin -9.22K%

Dividends & Yields

AUTL does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -53.81%
FCF Yield -26.44%
Dividend Details

Analyst Forecast

The average price target for AUTL is $10.5, which is 370.9% higher than the current price. The consensus rating is "Strong Buy".

Price Target $10.5
Price Target Difference 370.9%
Analyst Consensus Strong Buy
Analyst Count 4
Stock Forecasts

Scores

Altman Z-Score -0.57
Piotroski F-Score 3